Stock Ratings / Health Care / CELC / financials

CDNA (69) ACHC (37) VCYT (74) CLOV (30) ⌘ Pro Terminal →

Celcuity Inc. (CELC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$69.30 -0.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $69.14

Celcuity Inc. (CELC) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $3.39B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $69.14 (-0.23%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CELC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY CELC SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$67.94-16.7% Next Q

Q2 (-2Q)

Grade E$56.58+15.3% Next Q

Q3 (-1Q)

Grade E$65.25+6.2% Next Q

Current

Grade D-$69.30-8.3% Hist 90D α

Trajectory: E (28) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CELC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CELC currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($77.67) and Max Pain ($72.77) forces dealer call-delta covering toward $158.57.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CELC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CELC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CELC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-4.3%	-$177.0M	-$153.5M	-45%
FY 2024	$4.00B	52%	-2.8%	-$111.8M	-$83.7M	-45%
FY 2023	$4.00B	52%	-1.7%	-$63.8M	-$53.8M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CELC)

✓Walkthrough of CELC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CELC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.89%▼ DESCENDING CHANNEL

2026-10-30O $68.47H $70.43L $67.42C $69.30VOL 700.1K

RES: $78.22SUP: $46.84SMA50: $77.67SMA200: $100.6

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CELC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CELC Butterfly Map → + Track CELC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CELC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CELC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CELC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CELC)

Health Care Rank #772 of 1016 ⚔️ CDNA vs CELC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CELC vs. CDNA, ACHC, VCYT, CLOV)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Celcuity Inc. (CELC) ranks #772 by composite RQD confidence (36/100, grade D-) and #196 by equity capitalization ($3.39B). Within this direct 5-issuer industry benchmark cohort, VCYT leads on earnings valuation at 63.2x trailing P/E, while VCYT leads on capital efficiency and profitability with 4.6% ROIC and 70.1% gross margin. VCYT currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with CELC at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CELC ACTIVE Celcuity Inc.	D-	36/100	—	—	-35.0%	-0.23%	$3.39B	Benchmark Subject
CDNA CareDx Inc.	C+	69/100	—	—	-8.2%	-0.85%	$3.70B	/cdna-vs-celc →
ACHC Acadia Healthcare Company Inc.	D-	37/100	—	—	-24.8%	-0.17%	$2.74B	/achc-vs-celc →
VCYT Veracyte Inc.	B	74/100	63.2x	70.1%	4.6%	+3.70%	$4.19B	/vcyt-vs-celc →
CLOV Clover Health Investments Corp. (Class A)	E	30/100	—	—	-29.3%	-4.38%	$2.43B	/clov-vs-celc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001603454

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Celcuity Inc. (CELC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$177.0M, operating cash flow of -$153.3M, and free cash flow of -$153.5M (-83.4% YoY). On the balance sheet, CELC closed FY2025 with $466.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$177.0M	-$153.3M	-$153.5M	$466.6M	—
FY2024 (FY)	2024-12-31	$0	-$111.8M	-$83.5M	-$83.7M	$245.1M	—
FY2023 (FY)	2023-12-31	$0	-$63.8M	-$53.8M	-$53.8M	—	—

3. CELC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CELC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Celcuity Inc. (NASDAQ: CELC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $69.30 (-0.23% 1D, market cap $3.39B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CELC ranks #772 in composite RQD confidence.

How does CELC compare to CDNA and ACHC in the Health Care sector?

Within the Health Care sector (Medical Specialities), CELC carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CDNA (CareDx Inc.) holds a C+ grade (69/100 RQD, P/E N/A, ROIC -8.2%, cap $3.70B) and ACHC (Acadia Healthcare Company Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -24.8%, cap $2.74B). Among the 5-stock peer group, VCYT leads on earnings multiple (63.2x) while VCYT leads on capital efficiency (4.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CELC?

Per CELC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001603454), Celcuity Inc. generated $0 in revenue, -$177.0M in net income, and -$153.5M in free cash flow against $466.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CELC trading relative to its 50-day, 200-day, and 52-week technical levels?

CELC last traded at $69.30 (-0.23% on volume of 820,666 shares), positioning the stock -10.78% below its 50-day simple moving average ($77.67) and -31.13% below its 200-day simple moving average ($100.63). Across its 52-week range of $53.54 to $151.02, CELC sits at the 16.2% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($60.64 to $77.96).

CELC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Celcuity Inc. (CELC)?

In FY 2025 (10-K), CELC converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: CELC RQD Cockpit CELC 12M Forecast CELC Earnings & Move CELC Dividends & DRIP CELC Insiders & 13F CELC Whale Options CELC Profit Sankey CELC News & Why